The soluble form of CTLA-4, capable of binding CD80, is implicated in the pathogenesis of several autoimmune diseases, in which sCTLA-4 is able to inhibit early T-cell activation by blocking the interaction between CD80 and the costimulatory receptor CD28. The gene discussed is CD28; the disease is autoimmune disease.